Glen Clack

4.8k total citations · 1 hit paper
61 papers, 3.3k citations indexed

About

Glen Clack is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Glen Clack has authored 61 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 17 papers in Molecular Biology. Recurrent topics in Glen Clack's work include Estrogen and related hormone effects (16 papers), Cancer Genomics and Diagnostics (8 papers) and Bone health and treatments (8 papers). Glen Clack is often cited by papers focused on Estrogen and related hormone effects (16 papers), Cancer Genomics and Diagnostics (8 papers) and Bone health and treatments (8 papers). Glen Clack collaborates with scholars based in United Kingdom, United States and Singapore. Glen Clack's co-authors include Andrew Hughes, Caroline Dive, Matthew Krebs, Richard Eastell, Fiona Blackhall, R.A. Hannon, Malcolm Ranson, Tim Ward, Robert Szczepaniak‐Sloane and Lynsey Priest and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Glen Clack

60 papers receiving 3.3k citations

Hit Papers

Evaluation and Prognostic Significance of Circulating Tum... 2011 2026 2016 2021 2011 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
    2011 709 citations Matthew Krebs, Robert Szczepaniak‐Sloane et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Glen Clack United Kingdom 22 2.6k 1.3k 841 798 528 61 3.3k
Antonio Frassoldati Italy 27 1.7k 0.7× 876 0.7× 689 0.8× 705 0.9× 265 0.5× 156 2.8k
Martine P. Roudier United States 29 1.7k 0.6× 646 0.5× 1.8k 2.1× 1.3k 1.7× 178 0.3× 70 3.5k
Gaia Schiavon United Kingdom 28 2.5k 1.0× 1.9k 1.5× 1.7k 2.0× 1.5k 1.9× 339 0.6× 105 4.6k
Edda Simoncini Italy 26 1.7k 0.7× 1.1k 0.8× 753 0.9× 440 0.6× 360 0.7× 99 2.5k
Alan B. Tuck Canada 39 1.5k 0.6× 1.1k 0.8× 317 0.4× 2.1k 2.6× 537 1.0× 74 4.2k
Timothy W. Jacobs United States 27 1.1k 0.4× 752 0.6× 258 0.3× 567 0.7× 151 0.3× 50 2.5k
Giuseppe Badalamenti Italy 25 1.0k 0.4× 553 0.4× 764 0.9× 621 0.8× 317 0.6× 144 2.3k
Florian Schuetz Germany 26 1.3k 0.5× 604 0.5× 273 0.3× 450 0.6× 119 0.2× 79 2.2k
Klaus H. Metzeler Germany 29 1.0k 0.4× 912 0.7× 196 0.2× 2.3k 2.9× 226 0.4× 115 4.3k
Shmuel Yaccoby United States 38 3.0k 1.1× 454 0.4× 160 0.2× 3.0k 3.8× 145 0.3× 112 5.5k

Countries citing papers authored by Glen Clack

Since Specialization
Citations

This map shows the geographic impact of Glen Clack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glen Clack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glen Clack more than expected).

Fields of papers citing papers by Glen Clack

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Glen Clack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glen Clack. The network helps show where Glen Clack may publish in the future.

Co-authorship network of co-authors of Glen Clack

This figure shows the co-authorship network connecting the top 25 collaborators of Glen Clack. A scholar is included among the top collaborators of Glen Clack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Glen Clack. Glen Clack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Clack, Glen, Christopher M. Moore, Linette Ruston, et al.. (2024). A Phase 1 Randomized, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enteric-Coated Stabilized Sulforaphane (SFX-01) in Male Participants. Advances in Therapy. 42(1). 216–232. 1 indexed citations
2.
Krebs, Matthew, Ruth Plummer, Filip De Vos, et al.. (2023). A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer. The Oncologist. 28(12). e1248–e1258. 1 indexed citations
3.
Yap, Timothy A., Matthew Krebs, Sophie Postel‐Vinay, et al.. (2021). Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research. 27(19). 5213–5224. 71 indexed citations
4.
5.
Greystoke, Alastair, G. W. Harris, Martin Jenkins, et al.. (2013). Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: A short communication. Journal of Pharmaceutical and Biomedical Analysis. 84. 184–188. 3 indexed citations
6.
Finkelman, Richard D. & Glen Clack. (2012). The Androgen Receptor in Castration-Resistant Prostate Cancer: Still a Clinical Opportunity?. Journal of Cancer Science & Therapy. 1(S5). 2 indexed citations
7.
Poznak, Catherine Van, Andreas Makris, Glen Clack, David H. Barlow, & Richard Eastell. (2012). Lipid profiles within the SABRE trial of anastrozole with and without risedronate. Breast Cancer Research and Treatment. 134(3). 1141–1147. 7 indexed citations
8.
Hannon, R.A., Richard D. Finkelman, Glen Clack, et al.. (2012). Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study. Bone. 50(4). 885–892. 21 indexed citations
9.
Hou, Jianmei, Matthew Krebs, Tim Ward, et al.. (2011). Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer. American Journal Of Pathology. 178(3). 989–996. 343 indexed citations
10.
Krebs, Matthew, Jianmei Hou, Robert Szczepaniak‐Sloane, et al.. (2011). Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. Journal of Thoracic Oncology. 7(2). 306–315. 371 indexed citations
11.
Khoja, Leila, Alison Backen, Lia P. Menasce, et al.. (2011). A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. British Journal of Cancer. 106(3). 508–516. 208 indexed citations
12.
Poznak, Catherine Van, R.A. Hannon, John R. Mackey, et al.. (2010). Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial. Journal of Clinical Oncology. 28(6). 967–975. 164 indexed citations
13.
Eastell, Richard, Judith E. Adams, Robert E. Coleman, et al.. (2008). Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. Journal of Clinical Oncology. 26(7). 1051–1057. 306 indexed citations
14.
Renshaw, Lorna, Vivien N. Jacobs, Michael Fennell, et al.. (2008). Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Research and Treatment. 114(2). 211–221. 15 indexed citations
15.
Hodgson, Darren, et al.. (2008). Biomarkers in oncology drug development. Molecular Oncology. 3(1). 24–32. 23 indexed citations
16.
Eastell, Richard, et al.. (2006). Effect of an Aromatase Inhibitor on Bone Mineral Density and Bone Turnover Markers: 2 year Results of the 'Arimidex' (Anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial. Journal of Bone and Mineral Research. 2 indexed citations
17.
Green, Tim, Laurent Hennequin, Patrick A. Plé, et al.. (2005). Pre-clinical and early clinical activity of the highly selective, orally available, dual Src/Abl kinase inhibitor AZD0530. 65. 1463–1463. 7 indexed citations
18.
19.
Duffy, Simon P., Trachette L. Jackson, Mark Lansdown, et al.. (2003). The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data. BJOG An International Journal of Obstetrics & Gynaecology. 110(12). 1099–1106. 21 indexed citations
20.
Vorobiof, Daniel, Ulrich R. Kleeberg, R. Pérez-Carrión, et al.. (1999). A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex®) with intramuscular formestane in postmenopausal women with advanced breast cancer. Annals of Oncology. 10(10). 1219–1225. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonio Frassoldati Breakdown of academic impact, for papers by Martine P. Roudier Breakdown of academic impact, for papers by Gaia Schiavon Breakdown of academic impact, for papers by Edda Simoncini Breakdown of academic impact, for papers by Alan B. Tuck Breakdown of academic impact, for papers by Timothy W. Jacobs Breakdown of academic impact, for papers by Giuseppe Badalamenti Breakdown of academic impact, for papers by Florian Schuetz Breakdown of academic impact, for papers by Klaus H. Metzeler Breakdown of academic impact, for papers by Shmuel Yaccoby
Rankless by CCL
2026